Form 4: Director David Kupfer Receives Minerva Neurosciences Options

Minerva Neurosciences director David Kupfer was granted 50,000 stock options as part of his non-employee director compensation.

Summary

• Director David Kupfer was granted 50,000 stock options to purchase common stock in Minerva Neurosciences, Inc.
• The options have an exercise price of $4.68 per share.
• The grant date for these options is June 3, 2026.
• The options are set to expire on June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in four equal quarterly installments starting three months after June 3, 2026, contingent upon continued service as a non-employee director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of quarterly vesting schedules for director equity is consistent with standard governance practices for small-cap biotech firms.
• The 10-year expiration term for stock options is a standard industry benchmark for executive and director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first 1/4 of the options on September 3, 2026.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, Insider Trading, Stock Options, Director Compensation